ONCOS-102 Shows Promise in Combination Mesothelioma Treatment

ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving forward with another study combining ONCOS-102 with a checkpoint inhibitor drug such as Keytruda (pembrolizumab) or Opdivo (nivolumab), along with chemotherapy. “We have seen enough data at this point to be going full-steam ahead with larger randomized trials,” Dr. Magnus Jaderberg, chief medical officer at Targovax, told The Mesothelioma Center at Asbestos.com. “The data points to a real benefit with this emerging combination.” Find Clinical Trials for Mesothelioma Patients Get free help finding and enrolling in a mesothelioma clinical trial today! Find a Clinical Trial Survival Times Increase The drug combination including ONCOS-102 had a median progression-free survival of 8.4 months, compared to 6.8 months for the control group receiving only chemotherapy. Patients receiving the immunotherapy vaccine showed a 90% control rate, 7% better than the control group. The median progression-free survival was 4.5 months for the combination. Results are considered still emerging and are expected to change...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Source: BMJ Comments - Category: General Medicine Source Type: forums
Publication date: Available online 19 February 2020Source: The LancetAuthor(s): Sarah Fidler, Wolfgang Stöhr, Matt Pace, Lucy Dorrell, Andrew Lever, Sarah Pett, Sabine Kinloch-de Loes, Julie Fox, Amanda Clarke, Mark Nelson, John Thornhill, Maryam Khan, Axel Fun, Mikaila Bandara, Damian Kelly, Jakub Kopycinski, Tomáš Hanke, Hongbing Yang, Rachel Bennett, Margaret JohnsonSummaryBackgroundAntiretroviral therapy (ART) cannot cure HIV infection because of a persistent reservoir of latently infected cells. Approaches that force HIV transcription from these cells, making them susceptible to killing—termed...
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: Available online 19 February 2020Source: Microbial PathogenesisAuthor(s): Ali Dalir Ghaffari, Abdolhossein Dalimi, Fatemeh Ghaffarifar, Majid PirestaniAbstractToxoplasmosis, caused by Toxoplasma gondii, is a common parasitic disease, affecting almost one-third of the world's population. Currently, there are no effective treatments for inhibiting the formation of chronic tissue cysts in infected hosts. Thus, the production of appropriate vaccines against this pathogen is an important goal to avoid toxoplasmosis. considering the role of rhoptry antigens like ROP16 in virulence and satisfactory immunogenicit...
Source: Microbial Pathogenesis - Category: Infectious Diseases Source Type: research
Publication date: Available online 18 February 2020Source: Journal of Global Antimicrobial ResistanceAuthor(s): Rayane Rafei, Malaik Hawli, Marwan Osman, Fouad Dabboussi, Monzer HamzeAbstractThis review aimed to provide an updated scenario of the Group A Streptococcus (GAS) epidemiology in the Middle Eastern and North African (MENA) region with a special spotlight on the most prevalent emm types and macrolide resistance profiles. While the burden of invasive GAS infections is elusive to assess in the MENA region, the GAS prevalence ranged from 2.5% to up 42.4% in pharyngitis patients and from 2.4% to up 35.4% in healthy ca...
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
Publication date: Available online 3 January 2020Source: Seminars in Cancer BiologyAuthor(s): Kelly Olino, Tristen Park, Ntia AhujaAbstractAdvances in immunotherapy, most notably antibodies targeting the inhibitory immune receptors cytotoxic T-lymphocyte associated protein 4 (CTLA-4/CD152), programmed death protein 1 (PD-1/CD279) and programmed death-ligand 1 (PD-L1/B7H1/CD274) have become effective standard therapies in advanced malignancies including melanoma,1–4 merkel cell carcinoma5, urological cancers6–8, non-small cell lung cancer9–11, mis-match repair (MMR) deficient tumors12, and Hodgkin lymphoma...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
This study is an important step forward in highlighting C1q as a new prognostic candidate biomarker for a range of carcinomas. Methods Oncomine Database Analysis The expression levels of C1QA, C1QB, and C1QC genes in various carcinomas were analyzed using Oncomine (www.oncomine.org), a cancer microarray database and web-based data mining platform from genome-wide expression analyses (22, 23). We compared the differences in mRNA level between normal tissue and carcinoma. The mRNA expression levels in neoplastic tissues compared to the healthy tissues were obtained as the parameters of p-value 2, and gene ranking in the t...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This study aimed to explore whether a correlation exists between the incidence and mortality of cancers and normalized internet search volumes on the big data platform, Baidu. We also assessed whether the distribution of people who searched for specific types of cancer differed by gender. Finally, we determined whether there were regional disparities among people who searched the Web for cancer-related information. Methods: Standard Boolean operators were used to choose search terms for each type of cancer. Spearman’s correlation analysis was used to explore correlations among monthly search index values for each can...
Source: Journal of Medical Internet Research - Category: General Medicine Authors: Source Type: research
Oncologists in Spain are recruiting patients for the randomized phase of the pleural mesothelioma clinical trial involving ONCOS-102, the promising immunotherapy vaccine. Optimism surrounding the trial stems from encouraging results obtained recently in the six-patient safety cohort used as a precautionary lead-in. The trial involves the vaccine in combination with standard-of-care chemotherapy for patients with inoperable disease. ONCOS-102 is a scientifically engineered adenovirus that is designed to activate a patient’s immune system to selectively target cancer cells. It is being developed by Targovax, a Scandina...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I Abstract The tumour-associated antigen 5T4 is an attractive target for cancer immunotherapy. However to date, reported 5T4-specific cellular immune responses induced by various immunisation platforms have been largely weak or non-existent. In the present study, we have evaluated a heterologous prime boost regime based on the simian adenovirus ChAdOx1 and modified vaccinia virus Ankara (MVA) expressing 5T4 for immunogenicity and tumour protective efficacy in a mouse cancer model. Vaccination-induced immune responses were strong, durable and attrib...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Scandinavian-based Targovax launched the latest immunotherapy clinical trial for pleural mesothelioma, hoping it delivers a better way to treat patients with asbestos-related diseases. The randomized phase Ib/II trial evaluates the performance of ONCOS-102, an engineered human adenovirus designed to induce systemic, anti-tumor responses. Researchers are administering the immunotherapy drug as first-line therapy in combination with chemotherapy using pemetrexed and cisplatin. “Based on what we’ve seen in our first study of patients with various solid tumor types, which is good tolerance and response in a couple ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: immunotherapy clinical trial immunotherapy for cancer mesothelioma mesothelioma clinical trials mesothelioma immunotherapy ONCOS 102 Source Type: news
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Clinical Trials | Environmental Health | Finland Health | France Health | Immunotherapy | Melanoma | Mesothelioma | Ovarian Cancer | Ovaries | PET Scan | Prostate Cancer | Skin Cancer | Spain Health | Study | Vaccines